1887

Abstract

It was found previously that human immunodeficiency virus type 1 (HIV-1)-irrelevant CD8 cytotoxic T lymphocytes (CTLs) from uninfected donors suppressed HIV-1 replication in a cell-contact-dependent manner. However, one of these CTL lines (CTL-3) also significantly suppressed HIV-1 replication through its supernatant. Here, the suppressive fraction from CTL-3 supernatant was purified and analysed by mass spectrometry. A protein band specific for the suppressive fraction was identified as arginine deiminase from , which catalyses the hydrolysis of arginine to citrulline. Addition of -arginine or the use of antibiotics against mycoplasma restored supernatant-mediated but not cell-contact-dependent suppression of HIV-1 replication by CTL-3, clearly indicating that arginine deiminase of in the supernatants suppressed HIV-1 replication, which is independent of CD8 T-cell-mediated HIV-1 suppression via cell contact. Arginine deiminase is known to be a chemotherapeutic agent against arginine-requiring tumours and these results suggest that it also has potential application in antiviral therapy.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81549-0
2006-06-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/6/1589.html?itemId=/content/journal/jgv/10.1099/vir.0.81549-0&mimeType=html&fmt=ahah

References

  1. Adachi A., Gendelman H. E., Koenig S., Folks T., Willey R., Rabson A., Martin M. A. 1986; Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284–291
    [Google Scholar]
  2. Borrow P., Lewicki H., Hahn B. H., Shaw G. M., Oldstone M. B. 1994; Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103–6110
    [Google Scholar]
  3. Curley S. A., Bomalaski J. S., Ensor C. M., Holtsberg F. W., Clark M. A. 2003; Regression of hepatocellular cancer in a patient treated with arginine deiminase. Hepatogastroenterology 50:1214–1216
    [Google Scholar]
  4. el-Farrash M. A., Kannagi M., Kuroda M. J., Yoshida T., Harada S. 1994; The mycoplasma-related inhibitor of HIV-1 reverse transcriptase has a DNase activity and is present in the particle-free supernatants of contaminated cultures. J Virol Methods 47:73–82 [CrossRef]
    [Google Scholar]
  5. Ensor C. M., Holtsberg F. W., Bomalaski J. S., Clark M. A. 2002; Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo . Cancer Res 62:5443–5450
    [Google Scholar]
  6. Kannagi M., Masuda T., Hattori T., Kanoh T., Nasu K., Yamamoto N., Harada S. 1990; Interference with human immunodeficiency virus (HIV) replication by CD8+ T cells in peripheral blood leukocytes of asymptomatic HIV carriers in vitro. J Virol 64:3399–3406
    [Google Scholar]
  7. Koyanagi Y., Miles S., Mitsuyasu R. T., Merrill J. E., Vinters H. V., Chen I. S. 1987; Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819–822 [CrossRef]
    [Google Scholar]
  8. Kristensen D. B., Imamura K., Miyamoto Y., Yoshizato K. 2000; Mass spectrometric approaches for the characterization of proteins on a hybrid quadrupole time-of-flight (Q-TOF) mass spectrometer. Electrophoresis 21:430–439 [CrossRef]
    [Google Scholar]
  9. Liu H., Ohashi T., Masuda T., Zhou X., Kubo M., Kannagi M. 2003; Suppression of HIV-1 replication by HIV-1-irrelevant CD8+ cytotoxic T lymphocytes resulting in preservation of persistently HIV-1-infected cells in vitro. Viral Immunol 16:381–393 [CrossRef]
    [Google Scholar]
  10. Lo S. C., Tsai S., Benish J. R., Shih J. W., Wear D. J., Wong D. M. 1991; Enhancement of HIV-1 cytocidal effects in CD4+ lymphocytes by the AIDS-associated mycoplasma. Science 251:1074–1076 [CrossRef]
    [Google Scholar]
  11. Mackewicz C. E., Blackbourn D. J., Levy J. A. 1995; CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci U S A 92:2308–2312 [CrossRef]
    [Google Scholar]
  12. McMichael A. J., Rowland-Jones S. L. 2001; Cellular immune responses to HIV. Nature 410:980–987 [CrossRef]
    [Google Scholar]
  13. Ohashi T., Kubo M., Kato H., Iwamoto A., Takahashi H., Fujii M., Kannagi M. 1999; Role of class I major histocompatibility complex-restricted and -unrestricted suppression of human immunodeficiency virus type 1 replication by CD8+ T lymphocytes. J Gen Virol 80:209–216
    [Google Scholar]
  14. O'Toole C., Lowdell M. 1990; Infection of human T cells with mycoplasma, inhibition of CD4 expression and HIV-1 gp120 glycoprotein binding, and infectivity. Lancet 336:1067
    [Google Scholar]
  15. Pulvertaft J. V. 1964; Cytology of Burkitt's tumour (African Lymphoma). Lancet 283:238–240 [CrossRef]
    [Google Scholar]
  16. Sasaki Y., Blanchard A., Watson H. L., Garcia S., Dulioust A., Montagnier L., Gougeon M. L. 1995; In vitro influence of Mycoplasma penetrans on activation of peripheral T lymphocytes from healthy donors or human immunodeficiency virus-infected individuals. Infect Immun 63:4277–4283
    [Google Scholar]
  17. Shang H., Miyakawa Y., Sasaki T., Nakashima H., Ito M. 1995; Suppression of HIV-1 reverse transcriptase activity by culture supernatants of mycoplasmas. Microbiol Immunol 39:987–993 [CrossRef]
    [Google Scholar]
  18. Vasudevachari M. B., Mast T. C., Salzman N. P. 1990; Suppression of HIV-1 reverse transcriptase activity by mycoplasma contamination of cell cultures. AIDS Res Hum Retroviruses 6:411–416 [CrossRef]
    [Google Scholar]
  19. Yamagata A., Kristensen D. B., Takeda Y., Miyamoto Y., Okada K., Inamatsu M., Yoshizato K. 2002; Mapping of phosphorylated proteins on two-dimensional polyacrylamide gels using protein phosphatase. Proteomics 2:1267–1276 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81549-0
Loading
/content/journal/jgv/10.1099/vir.0.81549-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error